Iron supplementation associated with loss of phenotype in autosomal dominant hypophosphatemic rickets

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 9, 2015, Pages 3388-3392

  Kapelari, Klaus ^a   Köhle, Julia ^a,b   Kotzot, Dieter ^a   Högler, Wolfgang ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ALKALINE PHOSPHATASE; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; FIBROBLAST GROWTH FACTOR 23; IRON; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS;

ARTICLE; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; BODY HEIGHT; BONE METABOLISM; CASE REPORT; CHILD; DISEASE ASSOCIATION; EXON; FAMILY HISTORY; FEMALE; FGF23 GENE; GENE MUTATION; GENETIC ANALYSIS; GROWTH DISORDER; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY; IRON THERAPY; MALE; ORTHOPEDIC SURGERY; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PLASTIC SURGERY; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT DURATION; DEFICIENCY; DIET SUPPLEMENTATION; FAMILIAL HYPOPHOSPHATEMIC RICKETS; RICKETS; TREATMENT OUTCOME;

CALCITRIOL; CHILD, PRESCHOOL; DIETARY SUPPLEMENTS; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; HUMANS; IRON; RICKETS; TREATMENT OUTCOME;

EID: 84941662752     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2391     Document Type: Article

References (22)

1. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997;82(2):674-681.
2. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60(6): 2079-2086.
3. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26(3):345-348.
4. Yan X, Yokote H, Jing X, et al. Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells. 2005;10(5):489-502.
5. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of Vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429-435.
6. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and Vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007;293(5):F1577-F1583.
7. Bai XY, Miao D, Goltzman D, Karaplis AC. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem. 2003;278(11):9843-9849.
8. Larsson T, Nisbeth U, Ljunggren O, Jppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64(6):2272-2279.
9. Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003;18(7):1227-1234.
10. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011;96(11):3541-3549.
11. Kruse K, Woelfel D, Strom TM. Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res. 2001;55(6):305-308.
12. Seton M, Jppner H. Autosomal dominant hypophosphatemic rickets in an 85 year old woman: characterization of her disease from infancy through adulthood. Bone. 2013;52(2):640-643.
13. Durham BH, Joseph F, Bailey LM, Fraser WD. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem. 2007;44(Pt 5):463-466.
14. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011;108(46):E1146-E1155.
15. Bozentowicz-Wikarek M, Kocełak P, Owczarek A, et al. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population? Clin Biochem. 2015; 48(6):431-436.
16. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793-1803.
17. Braithwaite V, Jones KS, Assar S, Schoenmakers I, Prentice A. Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children. Endocr Connect. 2014;3(1):1-10.
18. Imel EA, Gray AK, Padgett LR, Econs MJ. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. Bone. 2014;60: 87-92.
19. Braithwaite V, Prentice AM, Doherty C, Prentice A. FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol. 2012;2012(1):27.
20. Shimizu Y, Tada Y, YamauchiM,et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45(4):814-816.
21. Clinkenbeard EL, Farrow EG, Summers LJ, et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res. 2014;29(2): 361-369.
22. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007;22(4):520-526.